TOP > 外国特許検索 > CELLULAR-DISORDER INHIBITOR, MEDICINAL COMPOSITION CONTAINING SAID CELLULAR-DISORDER INHIBITOR FOR PREVENTION OR TREATMENT OF ORGAN DERANGEMENT CAUSED BY HYPOXEMIA, AND MEDICINAL COMPOSITION CONTAINING SAID CELLULAR-DISORDER INHIBITOR FOR PREVENTION OR TREATMENT OF ISCHEMIC CEREBROVASCULAR DISORDER

CELLULAR-DISORDER INHIBITOR, MEDICINAL COMPOSITION CONTAINING SAID CELLULAR-DISORDER INHIBITOR FOR PREVENTION OR TREATMENT OF ORGAN DERANGEMENT CAUSED BY HYPOXEMIA, AND MEDICINAL COMPOSITION CONTAINING SAID CELLULAR-DISORDER INHIBITOR FOR PREVENTION OR TREATMENT OF ISCHEMIC CEREBROVASCULAR DISORDER

外国特許コード F160008792
整理番号 (S2014-1592-N0,S2015-0263-N0)
掲載日 2016年8月4日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2015JP079023
国際公開番号 WO 2016060158
国際出願日 平成27年10月14日(2015.10.14)
国際公開日 平成28年4月21日(2016.4.21)
優先権データ
  • 特願2014-212064 (2014.10.16) JP
  • 特願2015-029698 (2015.2.18) JP
発明の名称 (英語) CELLULAR-DISORDER INHIBITOR, MEDICINAL COMPOSITION CONTAINING SAID CELLULAR-DISORDER INHIBITOR FOR PREVENTION OR TREATMENT OF ORGAN DERANGEMENT CAUSED BY HYPOXEMIA, AND MEDICINAL COMPOSITION CONTAINING SAID CELLULAR-DISORDER INHIBITOR FOR PREVENTION OR TREATMENT OF ISCHEMIC CEREBROVASCULAR DISORDER
発明の概要(英語) The present invention is a cellular-disorder inhibitor characterized by containing any one of peptides (a) to (g), a derivative thereof, or a salt or ester of these as an active ingredient.
従来技術、競合技術の概要(英語) BACKGROUND ART
Hemostatic coagulation factor 9 (F9) is involved in clotting, blood coagulation factors of the long-known and essential fatty acid, a protein known as the cause of hemophilia. F9 Is, in the course of the blood coagulation reaction, clotting factors and clotting factors (F11) 11 (F7) by 7, present between the light and heavy chains of an intermediate portion (Activation peptide (hereinafter, also referred to as F9-AP.) ) Is cut off, is activated. The cut F9-AP is also light and heavy chains connected by a disulfide bond and, as a single molecule of 1 to promote blood coagulation reaction. However, the function of the reports F9-AP not.
The present inventors, extension of the cell and cause F9-AP revealed, epithelial and endothelial damage was found to be effective as a therapeutic agent (see Patent Document 1).
However, a variety of causes, cell, organ, sufficient oxygen is not supplied to the tissue, cell, organ, subject to tissue is disturbed. Cell, organ, tissue sufficient oxygen is supplied as in the non-, a poorly water-soluble accident, disaster, asphyxiation, anesthesia accident hypoxemia; pneumonia, respiratory diseases and bronchial asthma; shock, myocardial infarction, disseminated intravascular coagulation syndrome such as impaired blood flow by organ failure and the like. Such hypoxia induced by impairment of organs such as methods of treatment include, hypothermia treatment method can be used (see non-patent document 1-2).
In addition, causes the death of as Japanese, stroke is a cancer, heart disease, pneumonia 4 then serving as the first. However, the first stroke is the heart of a lying to persist or site of 1, compared with the incidence of myocardial infarction, stroke and the incidence rate of 3-10 times, in regard to the prophylaxis and treatment of stroke is important is in the absence of undoubtedly. Stroke about 12 million deaths a year and, according to the cerebral infarction is 60%. Cerebral infarction exact incidence is unknown, roughly one million 100-200 population in 10, 40 and 10 before and after 600 years of age or older is estimated to be one million. Rapid super senior population in regard to advances, the incidence of cerebral infarction, cerebral infarction total number of patients, the number of fatalities due to cerebral infarction, the number of the person, is increasingly expected to increase. Currently, the most effective treatment of thrombolytic therapy is cerebral infarction. Recombinant tissue plasminogen activator (rt-PA, alteplase) intravenous administration of 4.5 that can be treated within one hour from the onset of ischemic cerebral vascular disease in a patient who has been determined to be carefully adapted to strongly recommended (see non-patent document 3-4). In addition, edaravone is expected brain protective effect for cerebral infarction (thrombosis, embolism) recommended as a method of treating a patient (see non-patent document 5).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NIHON UNIVERSITY
  • 発明者(英語)
  • HIDAI Chiaki
  • MASUKO Takashi
  • KITANO Hisataka
  • MAMIYA Atsushi
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
日本大学産官学連携知財センター(通称NUBIC,ニュービック)は,技術移転機関と知的財産本部の機能を兼ね備えた日本大学の産学連携の窓口です。
NUBICは,日本大学全教職員や大学院生・学部学生の豊富なアイデアや研究成果を,知的財産として戦略的に創出・保護・管理し,産業界のニーズとのマッチングを図り,企業の研究開発,新製品開発,新規事業の立上げが円滑に行われるようサポートいたします。
お気軽にご相談ください。

PAGE TOP

close
close
close
close
close
close